Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Chin

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
The Lancet. Oncology|April 5, 2017
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trialChristopher R Heery, Geraldine O'Sullivan-Coyne, Ravi A Madan, et al.
Breast Cancer Research and Treatment|October 25, 2017
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor studyLuc Y Dirix, Istvan Takacs, Guy Jerusalem, et al.
JAMA Oncology|January 4, 2019
Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor TrialRaffit Hassan, Anish Thomas, John J Nemunaitis, et al.
The Lancet. Oncology|September 6, 2016
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trialHoward L Kaufman, Jeffery Russell, Omid Hamid, et al.
Journal for Immunotherapy of Cancer|October 23, 2019
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymomaArun Rajan, Christopher R Heery, Anish Thomas, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
The Lancet. Oncology|April 5, 2017
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trialChristopher R Heery, Geraldine O'Sullivan-Coyne, Ravi A Madan, et al.
Breast Cancer Research and Treatment|October 25, 2017
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor studyLuc Y Dirix, Istvan Takacs, Guy Jerusalem, et al.
JAMA Oncology|January 4, 2019
Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor TrialRaffit Hassan, Anish Thomas, John J Nemunaitis, et al.
The Lancet. Oncology|September 6, 2016
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trialHoward L Kaufman, Jeffery Russell, Omid Hamid, et al.
Journal for Immunotherapy of Cancer|October 23, 2019
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymomaArun Rajan, Christopher R Heery, Anish Thomas, et al.
Pageof 4